-
公开(公告)号：WO2022034486A1
公开(公告)日：2022-02-17
申请号：PCT/IB2021/057350
申请日：2021-08-10
发明人： KATAKAM, Venkatesh
摘要： The present invention relates to novel green tea water-soluble film composition comprising (a) green tea extract, (b) water-soluble polymer selected from group consisting of sodium alginate, cross-linked polyacrylate and carrageenan, and (c) additives and the process for the preparation thereof. As per the present invention green tea is conveniently prepared by dissolving the novel water-soluble green tea film of the said invention in hot water. The present invention more specifically relates to the water-soluble film composition comprising (a) green tea extract, and (b) water-soluble polymer mixture consisting of sodium alginate and carrageenan.
-
公开(公告)号：WO2021064580A1
公开(公告)日：2021-04-08
申请号：PCT/IB2020/059122
申请日：2020-09-30
发明人： NARASIYAPPA, Purushothama , CHERUKURI, Kiran Kumar , JOSHI, Vivek Vijaya Kumar , SHIVAKUMAR, Pradeep , REDDY, Sreenivasa
IPC分类号： A61K9/00 , A61K31/4178
摘要： The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.
-
公开(公告)号：WO2019202521A1
公开(公告)日：2019-10-24
申请号：PCT/IB2019/053158
申请日：2019-04-17
IPC分类号： A61K31/167 , A61K9/16
摘要： The present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a fast dissolving film composition containing paracetamol and taste masking agent; wherein taste masking agent is a mixture of sodium carbonate, citric acid and magnesium aluminometasilicate.
-
公开(公告)号：WO2019123364A1
公开(公告)日：2019-06-27
申请号：PCT/IB2018/060421
申请日：2018-12-20
发明人： RAMPALLI, Sriram , UPALLA, Lav Kumar , CHERUKUVADA, Suryanarayan , PATNEEDI, Chanti Babu , DASARI, Gopala Krishna , SESHAGIRI, Vijaya Murali Mohan Rao
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention relates to novel crystalline and amorphous polymorphic forms of Ribociclib(l) mono succinate. (I) Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.
-
公开(公告)号：WO2019012353A1
公开(公告)日：2019-01-17
申请号：PCT/IB2018/054453
申请日：2018-06-18
IPC分类号： A61K31/473 , A61K31/58 , A61K8/63
摘要： The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.
-
公开(公告)号：WO2016001792A1
公开(公告)日：2016-01-07
申请号：PCT/IB2015/054675
申请日：2015-06-23
IPC分类号： A61K31/519 , A61P35/00 , C07D487/04
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/19 , A61K47/26 , C07D487/04
摘要： The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.
摘要翻译： 本申请提供衍生自培美曲塞非水合二钾的药物组合物及其方法。 本申请还提供了一种通过将需要的重组冻干组合物静脉内施用于有需要的患者来治疗癌症的方法。
-
7.发明申请
公开(公告)号：WO2015198258A1
公开(公告)日：2015-12-30
申请号：PCT/IB2015/054773
申请日：2015-06-25
IPC分类号： A61K31/575 , A61K31/57 , A61K9/20
CPC分类号： A61K9/2077 , A61K9/0095 , A61K31/575
摘要： The invention relates to a dispersible tablet composition comprising a therapeutically effective amount of Ursodiol or its pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable excipients, having disintegration time of less than 2 minutes in a dispersion medium. The invention further, relates to a method of administering the medicament in a liquid administration form containing Ursodiol, for the treatment of Primary biliary cirrhosis in adults and geriatrics, and cholestatic hepatic diseases in infants and children.
摘要翻译： 本发明涉及一种可分散片剂组合物，其包含治疗有效量的二硫酚或其药学上可接受的盐与一种或多种药学上可接受的赋形剂，在分散介质中具有小于2分钟的崩解时间。 本发明还涉及以含有乌司他丁的液体给药形式给予药物的方法，用于治疗成年人和老年病中的原发性胆汁性肝硬化，以及婴儿和儿童胆汁淤积性肝病。
-
公开(公告)号：WO2015114470A1
公开(公告)日：2015-08-06
申请号：PCT/IB2015/050008
申请日：2015-01-01
IPC分类号： A61K31/00
CPC分类号： C07F9/202 , C07B2200/13 , C07F9/17
摘要： The present invention relates to a process for preparation of Echothiophate Iodide Echothiophate Iodide (I) obtained by the process of the present invention is obtained as crystalline form designated as Form-SET. (I) The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.
摘要翻译： 本发明涉及通过本发明的方法得到的回波硫代磷酸回波偏碘酸碘（I）的制备方法，以结晶形式获得，形式为Form-SET。 （I）根据本发明的制备回波硫代磷酸酯（I）的方法是避免使用有害溶剂体系并提供高纯度的回波硫代碘（I）的环保方法。 所述高纯度回波硫代碘（I）结晶形式SET的药物组合物可用于治疗眼部疾病如青光眼。
-
公开(公告)号：WO2015075601A1
公开(公告)日：2015-05-28
申请号：PCT/IB2014/065954
申请日：2014-11-11
IPC分类号： A61K31/519
CPC分类号： C07D487/04 , A61K31/519
摘要： The present invention provides process for preparing crystalline Pemetrexed dipotassium (I) Form-SP9 formula (I) characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2θ° peaks selected from the XRPD peak set of 5.0, 12.5, 17.2, 20.8, 22.4, 25.7, 26.9 and 27.9 ± 0.2 2θ°. The invention also provides process for preparing its pharmaceutical composition thereof, which may be useful for anti-cancer treatment.
摘要翻译： 本发明提供了制备结晶培美曲塞二钾（I）Form-SP9式（I）的方法，其特征在于X射线粉末衍射图，其包含至少5个选自5.0,12.5,17.2,20.8的XRPD峰集合的特征2θ°峰 ，22.4,25.7,26.9和27.9±0.22θ°。 本发明还提供其制备其药物组合物的方法，其可用于抗癌治疗。
-
公开(公告)号：WO2015036898A2
公开(公告)日：2015-03-19
申请号：PCT/IB2014/064224
申请日：2014-09-03
发明人： UPALLA, Lavkumar , RAMPALLI, Sriram , PATNEEDI, Chantibabu , DANGUDUBIYYAM, Chandrasekhar , CHATURVEDI, Akshaykant
CPC分类号： C07D401/14 , C07C59/52 , C07C59/74
摘要： The present invention relates to novel pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate thereof. The present invention further relates to processes for preparation of the said substituted aryl acrylic acid addition salts of Crizotinib (I). The present application also provides pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate useful as active pharmaceutical ingredient in pharmaceutical composition comprising thereof, possessing anti-cancer activity.
摘要翻译： 本发明涉及Crizotinib（I）或其水合物或溶剂化物的新的药学上可接受的取代的芳基丙烯酸加成盐。 本发明还涉及制备Crizotinib（I）的所述取代的芳基丙烯酸加成盐的方法。 本申请还提供了具有抗癌活性的药学上可接受的取代的三唑酮（I）或其水合物或溶剂合物的取代的芳基丙烯酸加成盐，其可用作其药物组合物中作为活性药物成分。
-
-
-
-
-
-
-
-
-
搜索结果
82 条记录 (耗时 0.013 秒)
